X4 Pharmaceuticals, Inc. Appoints Diego Cadavid, M.D., as Chief Medical Officer
December 14, 2020 at 01:00 pm
Share
X4 Pharmaceuticals, Inc. announced the appointment of Diego Cadavid, M.D., as Chief Medical Officer. Dr. Cadavid will be responsible for the strategy, direction and execution of the company's clinical development programs. Dr. Cadavid brings more than 22 years of experience in drug development and academic research to X4, having led multiple programs through all phases of clinical development, including small molecules and biologics for the treatment of rare and immunological diseases. Most recently, Dr. Cadavid served as Senior Vice President and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases, including sickle cell disease and beta-thalassemia as well as muscular dystrophies.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
X4 PHARMACEUTICALS, INC. 
